You'll hear claims that gliptins (Januvia, etc) decrease cardiovascular risk in diabetes patients

November 2011

You'll hear claims that gliptins (Januvia, etc) decrease cardiovascular risk in diabetes patients.

This is based on a new meta-analysis that suggests gliptins don't increase cardiovascular risk...and MIGHT even decrease it.

But this analysis hasn't been peer-reviewed and published.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get quote

Table of Contents

Influenza changes in flu immunization this season
Bisphosphonates Actonel DR, a new delayed-release form of risedronate (Actonel), for postmenopausal osteoporosis
Bisphosphonates more controversy about how long patients should take bisphosphonates (alendronate, etc) for osteoporosis
Neurology & Pain new prescription analgesic cream for knee osteoarthritis called Zuacta (zucapsaicin 0.075%)
Gastroenterology when a patient on a chronic NSAID should also get a PPI, misoprostol, or an H2-blocker
Men's Health Saw palmetto will fall out of favour for treating benign prostatic hyperplasia (BPH)
Men's Health Staxyn (STAX-in), a new orally disintegrating tablet version of vardenafil (Levitra)
Men's Health daily Cialis (tadalafil) for benign prostatic hyperplasia (BPH)
Ophthalmology Glaucoma patients often ask which drugs to avoid
Diabetes You'll hear claims that gliptins (Januvia, etc) decrease cardiovascular risk in diabetes patients
Infectious Diseases treatment of community-acquired pneumonia in children
Edema how to handle drug-induced edema
Magnesium PPIs and hypomagnesemia are raising questions about when and how to use magnesium supplements